Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus

被引：3

作者：

Viudez, Antonio ^{[1
,2
]}

Crespo, Guillermo ^{[3
]}

Dorronsoro, Maria Luisa Gomez ^{[4
]}

Arozarena, Imanol ^{[2
,5
]}

Marin-Mendez, Juan Jesus ^{[6
]}

Custodio, Ana ^{[7
]}

Benavent, Marta ^{[8
]}

Goni, Saioa ^{[2
]}

Garcia-Paredes, Beatriz ^{[9
]}

Hern, Jorge ^{[10
]}

Durantez, Maika ^{[5
]}

Alonso, Vicente ^{[11
]}

Riesco, Del Carmen ^{[12
]}

Lopez, Carlos ^{[13
]}

Jimenez-Fonseca, Paula ^{[14
]}

San Vicente, Borja Lopez ^{[15
]}

Gonzalez-Borja, Iranzu ^{[2
,15
]}

Sevilla, Isabel ^{[16
]}

Hernandez-Garcia, Irene ^{[1
]}

Carmona-Bayonas, Alberto ^{[17
]}

Capdevila, Jaume ^{[10
]}

Perez-Sanz, Jairo ^{[2
]}

Garcia-Carbonero, Rocio ^{[12
]}

Perez-Ricarte, Leyre ^{[1
]}

Llanos, Marta ^{[18
]}

Vera, Ruth ^{[1
]}

De Jesus Acosta, Ana ^{[19
]}

机构：

[1] Inst Hlth Res Idisna, Complejo Hosp Navarra CHN, Dept Med Oncol, Pamplona, Spain

[2] Univ Publ Navarra UPNA, OncobionaTras Unit Navarrabiomed, CHN, Idisna, Pamplona, Spain

[3] Hosp Univ Burgos, Dept Med Oncol, Burgos, Spain

[4] Complejo Hosp Navarra, Dept Pathol, Idisna, Pamplona, Spain

[5] CHN, Canc Signalling, Navarrabiomed, Idisna, Pamplona, Spain

[6] Datbow SL, Ansoain, Spain

[7] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain

[8] Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain

[9] Hosp Univ San Carlos, Dept Med Oncol, Madrid, Spain

[10] Hosp Univ Vall DHebron, Dept Med Oncol, Barcelona, Spain

[11] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain

[12] Hosp Univ Doce Octubre, Dept Med Oncol, Madrid, Spain

[13] Hosp Univ Marques de Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain

[14] Hosp Univ Cent Asturias, Dept Med Oncol, ISPA, Oviedo, Spain

[15] Hosp Basurto, Dept Med Oncol, Bilbao, Spain

[16] Hosp Univ Virgen Victoria, Dept Med Oncol, Malaga, Spain

[17] UMU, Hosp Univ Morales Meseguer, Dept Med Oncol, IMI, Murcia, Spain

[18] Hosp Univ Canarias, Dept Med Oncol, Santa Cruz De Tenerife, Spain

[19] Johns Hopkins Univ Hosp, Dept Med Oncol, Baltimore, MD 21287 USA

来源：

PANCREATOLOGY | 2021年 / 21卷 / 01期

关键词：

Metastatic pancreatic neuroendocrine tumor; MGMT; NDRG-1; PHLDA-3; Immunohistochemistry; Biomarker; Predictive factor; Prognosis factor; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; EXPRESSION; MGMT; TEMOZOLOMIDE; SUPPRESSOR; NDRG1;

D O I：

10.1016/j.pan.2020.12.009

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Pancreatic neuroendocrine tumors are rare neoplasms for which few predictive and/or prognostic biomarkers have been validated. Our previous work suggested the potential of the combined expression of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) as prognostic factors for relapse and survival. Methods: In this new multicenter study we evaluated immunohistochemistry expression in 76 patients with advanced PanNET who were treated with capecitabine-temozolomide or everolimus. Based on the immunohistochemistry panel, an immunohistochemistry prognostic score (IPS) was developed. Results: In patients treated with capecitabine and temozolomide, low IPS was an independent prognostic factor for progression-free-survival and overall-survival. Similar findings were observed with highest IPS for overall-survival in patients treated with everolimus. Conclusion: From our knowledge, it is the first time that a simple IPS could be useful to predict outcome for patients with metastatic pancreatic neuroendocrine tumors treated with everolimus or capecitabine and temozolomide. (C) 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.

引用

页码：215 / 223

页数：9

共 50 条

[1] SILVELUL Project: Development of a New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Viudez, A.
Crespo, G.
Gomez-Dorronsoro, M. L.
Benavent, M.
Hernando, J.
Garcia-Paredes, B.
Sevilla, I
Alonso, V
Lopez, C.
Custodio, A.
Llanos, M.
De Jesus-Acosta, A.
[J]. NEUROENDOCRINOLOGY, 2020, 110 : 158 - 158
[2] GETNE-SILVELUL study: A new immunohistochemical score (SPI) in patients (pts) with pancreatic neuroendocrine tumors (PanNET) treated with everolimus or captem.
Viudez, Antonio
Crespo, Guillermo
Gomez-Dorronsoro, Maria Luisa
Benavent, Marta
Hernando, Jorge
Goni, Saioa
Garcia, Beatriz
Sevilla, Isabel
Alonso, Vicente
Gonzalez-Borja, Iranzu
Lopez, Carlos
Custodio, Ana
Hernandez, Irene
Llanos, Marta
Carmona, Alberto
Perez-Sanz, Jairo
San Vicente, Borja Lopez
De Jesus-Acosta, Ana
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] SILVELUL SCORE: An original or modified immunohistochemical score (IPS or mIPS) in patients (pts) with pancreatic neuroendocrine tumours (PanNET) treated with everolimus or CAPTEM
Viudez, A.
Crespo, G.
Gomez-Dorronsoro, M. L.
Custodio, A.
Benavent, M.
Garcia Paredes, B.
Hernando, J.
Alonso-Orduna, V.
Goni, S.
Lopez, C.
Jimenez-Fonseca, P.
Gonzalez, I.
Lopez-San Vicente, B.
Sevilla Garcia, I.
Hernandez, I.
Carmona, A.
Perez Sanz, J.
Lopez Ricarte, L.
Marin, J.
De Jesus-Acosta, A.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S775 - S775
[4] GETNET-SILVELUL study: An original or modified immunohistochemical score (IPS or mIPS) in patients (pts) with pancreatic neuroendocrine tumors (PanNET) treated with everolimus or CAPTEM
Viudez, A.
Crespo, G.
Gomez Dorronsoro, M.
Garcia Paredes, B.
Custodio, A.
Hernando, J.
Sevilla, I.
Goni, S.
Lopez, C.
Benavent, M.
Jimenez Fonseca, P.
Alonso-Orduna, V.
Gonzalez Borja, I.
Hernandez, I.
Llanos Munoz, M.
Carmona, A.
Perez Sanz, J.
Lopez-San Vicente, B.
De Jesus-Acosta, A.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S170 - S170
[5] Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
Yao, James C.
Shah, Manisha H.
Ito, Tetsuhide
Bohas, Catherine Lombard
Wolin, Edward M.
Van Cutsem, Eric
Hobday, Timothy J.
Okusaka, Takuji
Capdevila, Jaume
de Vries, Elisabeth G. E.
Tomassetti, Paola
Pavel, Marianne E.
Hoosen, Sakina
Haas, Tomas
Lincy, Jeremie
Lebwohl, David
Oberg, Kjell
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (06): : 514 - 523
[6] Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus
Cella, C. A.
Spada, F.
Labanca, V
Radice, D.
Rubino, M.
Zorzino, L.
Fazio, N.
[J]. NEUROENDOCRINOLOGY, 2017, 105 : 3 - 3
[7] SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus
De Jesus-Acosta, A.
Crespo Herrero, G.
Gomez-Dorronsoro, M. L.
Alonso, V.
Riesco Martinez, M. C.
Custodio, A.
Lopez, C.
Benavent, M.
Carmona Bayonas, A.
Jimenez-Fonseca, P.
Llanos, M.
Lopez De San Vicente, B.
Arrazubi Arrula, V.
Grandez, R.
Gonzalez-Borja, I.
Goni, S.
Arozarena, I.
Baretti, M.
Viudez, A.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[8] Neoadjuvant Capecitabine/Temozolomide (CAPTEM) for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
Squires, M. H.
Rossfeld, K. K.
Konda, B.
Shah, M.
Dillhoff, M.
Abdel-Misih, S.
Pawlik, T.
Cloyd, J.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S138 - S139
[9] Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience
Yao, James C.
Phan, Alexandria T.
Jehl, Valentine
Shah, Gaurav
Meric-Bernstam, Funda
[J]. CANCER RESEARCH, 2013, 73 (05) : 1449 - 1453
[10] Outcomes of patients treated with capecitabine and temozolamide (CapTem) for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs
Peixoto, Renata D'Alpino
Noonan, Krista
Kennecke, Hagen F.
Lim, Howard John
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)

← 1 2 3 4 5 →